Su1570 IMPACT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS CIRRHOSIS ON INPATIENT OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION

Sa1634 THE DIAGNOSTIC MODELS BASED ON MACHINE LEARNING FOR IDENTIFYING ADVANCED FIBROSIS AND CIRRHOSIS IN CHRONIC HEPATITIS B PATIENTS WITH CONCUEERNT ...

Mo1631 DISTINCT PATTERNS OF STELLATE CELL PHENOTYPIC MODULATION IN ALCOHOLIC AND METABOLIC DYSFUNCTION-ASSOCIATED CIRRHOSIS

Su1605 VALIDATION OF AGILE 3+ AND AGILE 4 FOR MASLD WITH ADVANCED FIBROSIS AND CIRRHOSIS IN A CANADIAN COHORT

Mo1514 PREVALENCE OF MASLD, METALD, ALD AND CIRRHOSIS AMONG OVERWEIGHT AND OBESE INDIVIDUALS IN THE UNITED STATES: A PROSPECTIVE STUDY

103 STATIN THERAPY AND IMPROVED WAITLIST OUTCOMES IN LIVER TANS PANT CANDIDATES WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) CIRRHOSIS

684 THE LIVER FRAILTY INDEX (LFI) IMPROVES MORTALITY RISK PREDICTION OVER MELD 3.0 ALONE FOR WOMEN, OLDER ADULTS, AND OBESE PATIENTS WITH CIRRHOSIS

Su1527 HIGHER INCIDENCE OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN LEAN VS. OVERWEIGHT/OBESE VETERANS WITH MASLD

Tu1527 COVID-19 INFECTION IS AN INDEPENDENT RISK FACTOR FOR CIRRHOSIS DECOMPENSATION

Su1580 PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISAESE (MASLD)-RELATED CIRRHOSIS IN THE ...